alendronate has been researched along with medroxyprogesterone in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Balske, A; Chilvers, CE; Christiansen, C; Daley, M; Hosking, D; McClung, M; Ravn, P; Ross, P; Thompson, D; Wasnich, R; Yates, AJ | 1 |
| Araujo, GL; Domingo, P; Fajreldines, F; Giglione, F; Noriega, R; Rivoira, MA; Ulla, MR | 1 |
| Greenspan, SL; Parker, RA; Resnick, NM | 1 |
| Cho, BY; Kim, SW; Kim, SY; Lee, HK; Park, DJ; Park, KS; Shin, CS | 1 |
1 review(s) available for alendronate and medroxyprogesterone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for alendronate and medroxyprogesterone
| Article | Year |
|---|---|
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Topics: Alendronate; Bone Density; Double-Blind Method; Drug Combinations; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Forearm; Humans; Lumbar Vertebrae; Medroxyprogesterone; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Postmenopause; Progesterone Congeners | 1998 |
The effect of hormone replacement on physical performance in community-dwelling elderly women.
Topics: Accidental Falls; Activities of Daily Living; Aged; Alendronate; Bone Density Conservation Agents; Boston; Calcium; Cognition; Double-Blind Method; Estrogens, Conjugated (USP); Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone; Motor Activity; Osteoporosis, Postmenopausal; Postural Balance; Psychomotor Performance; Treatment Failure; Vitamin D; Walking | 2005 |
Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen; Collagen Type I; Estrogens; Female; Femur Neck; Humans; Korea; Longitudinal Studies; Medroxyprogesterone; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Spine; Time Factors | 2005 |
2 other study(ies) available for alendronate and medroxyprogesterone
| Article | Year |
|---|---|
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
[Effects on bone mass of oral alendronate, hormone replacement therapy and combined regimes in post-menopausal women: preliminary report on a comparative study].
Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Bone Diseases, Metabolic; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone; Middle Aged; Prospective Studies | 1997 |